ATE555783T1 - Mittel zur behandlung oder prävention von ischämischer neuropathie - Google Patents

Mittel zur behandlung oder prävention von ischämischer neuropathie

Info

Publication number
ATE555783T1
ATE555783T1 AT04799962T AT04799962T ATE555783T1 AT E555783 T1 ATE555783 T1 AT E555783T1 AT 04799962 T AT04799962 T AT 04799962T AT 04799962 T AT04799962 T AT 04799962T AT E555783 T1 ATE555783 T1 AT E555783T1
Authority
AT
Austria
Prior art keywords
agents
treating
preventing ischemic
ischemic neuropathy
independently hydrogen
Prior art date
Application number
AT04799962T
Other languages
English (en)
Inventor
Kazuhito Ikeda
Toru Kimura
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Application granted granted Critical
Publication of ATE555783T1 publication Critical patent/ATE555783T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82Xanthenes
    • C07D311/84Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D311/86Oxygen atoms, e.g. xanthones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02Oxygen as only ring hetero atoms
    • C12P17/06Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10Preparation or pretreatment of starting material
    • A61K2236/11Preparation or pretreatment of starting material involving culturing conditions, e.g. cultivation in the dark or under defined water stress

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
AT04799962T 2003-12-05 2004-11-30 Mittel zur behandlung oder prävention von ischämischer neuropathie ATE555783T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003406804 2003-12-05
PCT/JP2004/018114 WO2005053678A1 (ja) 2003-12-05 2004-11-30 虚血性神経障害治療又は予防剤

Publications (1)

Publication Number Publication Date
ATE555783T1 true ATE555783T1 (de) 2012-05-15

Family

ID=34650292

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04799962T ATE555783T1 (de) 2003-12-05 2004-11-30 Mittel zur behandlung oder prävention von ischämischer neuropathie

Country Status (7)

Country Link
US (2) US20070105948A1 (de)
EP (1) EP1693060B1 (de)
JP (1) JP4820170B2 (de)
KR (1) KR20070029123A (de)
AT (1) ATE555783T1 (de)
ES (1) ES2382808T3 (de)
WO (1) WO2005053678A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025775A1 (en) * 2009-08-24 2011-03-03 Alterman Ron L Apparatus for trans-cerebral electrophoresis and methods of use thereof
US9040062B2 (en) 2010-08-06 2015-05-26 Sumitomo Dainippon Pharma Co., Ltd. Preparation for treatment of spinal cord injury
CA2827869C (en) 2011-02-25 2019-04-02 Dainippon Sumitomo Pharma Co., Ltd. Therapeutic agent for corneal sensory nerve damage containing semaphorin inhibitor as active ingredient
JP6742343B2 (ja) 2016-01-15 2020-08-19 大日本住友製薬株式会社 2環性複素環化合物
JP7551502B2 (ja) * 2018-12-12 2024-09-17 住友ファーマ株式会社 新規投与方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580609A1 (de) * 1991-03-22 1994-02-02 Xenova Limited Pharmazeutische xanthonderivate
US5266580A (en) * 1992-01-24 1993-11-30 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration with droperidol
JPH08165237A (ja) * 1994-12-12 1996-06-25 Bio Kosumosu:Kk 血液流動性改善剤
WO2002009756A1 (en) * 2000-07-28 2002-02-07 Sumitomo Pharmaceuticals Company, Limited Nerve regeneration promoters containing semaphorin inhibitor as the active ingredient
JP4633897B2 (ja) * 2000-08-17 2011-02-16 長瀬産業株式会社 神経突起伸長剤
WO2003062440A1 (en) * 2002-01-21 2003-07-31 Sumitomo Pharmaceuticals Co., Ltd. Xanthone derivative
EP1475382B1 (de) * 2002-01-24 2008-12-10 Dainippon Sumitomo Pharma Co., Ltd. Verbindungen als semaphorininhibitoren

Also Published As

Publication number Publication date
JP4820170B2 (ja) 2011-11-24
EP1693060A1 (de) 2006-08-23
US20070105948A1 (en) 2007-05-10
KR20070029123A (ko) 2007-03-13
WO2005053678A1 (ja) 2005-06-16
US20110105599A1 (en) 2011-05-05
ES2382808T3 (es) 2012-06-13
EP1693060A4 (de) 2008-09-17
JPWO2005053678A1 (ja) 2007-06-28
EP1693060B1 (de) 2012-05-02

Similar Documents

Publication Publication Date Title
GB0225475D0 (en) Therapeutic agents
GB0225474D0 (en) Therapeutic agents
GB0318447D0 (en) Therapeutic agents
GB0223038D0 (en) Therapeutic compounds
CY1110901T1 (el) Στερεοϊσομερεις ενωσεις και μεθοδοι για την αγωγη γαστρεντερικων διαταραχων και διαταραχων του κεντρικου νευρικου συστηματος
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
IL173396A0 (en) Piperazine derivatives and their use as therapeutic agents
DE60026155D1 (de) Einige alkylendiamin-substituierte heterocyclen
DE60314633D1 (de) Substituierte 1,3-diphenylprop-2-en-1-on derivate, deren herstellung und anwendungen
UY28011A1 (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
DE60119784D1 (de) Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
NO20064282L (no) Morfolinforbindelser
GB0207495D0 (en) Organic compounds
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
SE0400043D0 (sv) New compounds
BRPI0416720B8 (pt) composto, processo para a preparação de um composto, composição fungicida e método de combate curativo ou preventivo dos fungos fitopatogênicos de culturas
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
ATE556712T1 (de) A2a antagonisten zur behandlung von motorischen störungen
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
ECSP066484A (es) Compuestos y metodos para el tratamiento de dislipidemia
ATE555783T1 (de) Mittel zur behandlung oder prävention von ischämischer neuropathie
MY147404A (en) Process for preparation of n-benzoyl-staurosporine
AU2003213661A8 (en) Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders